Brunilda Shtylla is Chief Business Officer of Kivu Bioscience, where she leads corporate strategy, business development, and partnership initiatives as the company advances its antibody-drug conjugate (ADC) pipeline through clinical development and expands its strategic collaborations.

Ms. Shtylla brings more than 25 years of cross-functional experience spanning biotechnology, medical devices, finance, and strategic transactions. Most recently, she served as Chief Business Officer at Sutro Biopharma, where she led business strategy and corporate development efforts, advancing the company’s cell-free platform through technology collaborations, licensing agreements, and strategic partnerships. During her tenure, she contributed to transactions representing more than $5 billion in total deal value across multiple platform and asset partnerships.

Earlier in her career, Ms. Shtylla advised leading organizations including Genentech, GRAIL, and Edwards Lifesciences on technology development, transaction diligence, operational strategy, and licensing initiatives. She also held multiple leadership roles at LifeScan, a Johnson & Johnson company, where she supported the development and commercialization of the OneTouch Verio® blood glucose monitoring system and managed key external technology partnerships.

Ms. Shtylla holds an MBA from Stanford Graduate School of Business, an MS in Mathematics from Youngstown State University, and a BS in Business from Wayne State University.